Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Staging and clinical prognostic factors for small-cell lung cancer
Autore:
Argiris, A; Murren, JR;
Indirizzi:
Northwestern Univ, Sch Med, Chicago, IL 60611 USA Northwestern Univ Chicago IL USA 60611 iv, Sch Med, Chicago, IL 60611 USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA Northwestern Univ Chicago IL USA 60611 ns Canc Ctr, Chicago, IL 60611 USA Yale Univ, Sch Med, New Haven, CT USA Yale Univ New Haven CT USAYale Univ, Sch Med, New Haven, CT USA Yale Univ, Ctr Canc, New Haven, CT USA Yale Univ New Haven CT USAYale Univ, Ctr Canc, New Haven, CT USA
Titolo Testata:
CANCER JOURNAL
fascicolo: 5, volume: 7, anno: 2001,
pagine: 437 - 447
SICI:
1528-9117(200109/10)7:5<437:SACPFF>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW INVOLVEMENT; POSITRON-EMISSION-TOMOGRAPHY; LABELED MONOCLONAL-ANTIBODY; SERUM LACTATE-DEHYDROGENASE; COMBINED-MODALITY TREATMENT; ONCOLOGY-GROUP EXPERIENCE; LONG-TERM SURVIVAL; CT-GUIDED BIOPSY; ENOLASE S-NSE; BRAIN METASTASES;
Keywords:
small cell lung cancer; staging; prognostic factors;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
109
Recensione:
Indirizzi per estratti:
Indirizzo: Argiris, A Northwestern Univ, Sch Med, 676 N Clair St, Chicago, IL 60611 USA Northwestern Univ 676 N Clair St Chicago IL USA 60611 60611 USA
Citazione:
A. Argiris e J.R. Murren, "Staging and clinical prognostic factors for small-cell lung cancer", CANCER J, 7(5), 2001, pp. 437-447

Abstract

The two-stage system introduced by the Veterans' Affairs Lung Study Group continues to be widely utilized in small-cell lung cancer (SCLC), mainly because of its simplicity and clinical utility. Approximately one third of patients with SCLC present with limited-stage disease, which is defined as disease that can be encompassed in a tolerable radiation field. However, thisdefinition is controversial when it is applied to the staging classification of patients with locoregionally advanced disease manifested as the presence of an ipsilateral pleural effusion, contralateral supraclavicular lymphadenopathy, or contralateral mediastinal lymphadenopathy. The more descriptive TNM system is useful for patients with disease limited to the lung, when surgical resection may be feasible; this occurs in far less than 10% of cases. As shown by clinical studies and autopsy data, metastatic disease frequently involves the liver, adrenals, bone, bone marrow, and brain. History and physical examination, complete blood count and chemistry studies, chest x-ray studies, computed tomography of the chest or upper abdomen, computed tomographic scanning or magnetic resonance imaging of the brain, and bone scans are recommended for the pretreatment evaluation of patients with SCLC. A bone marrow biopsy may be omitted for patients with normal blood counts, normal lactate dehydrogenase level, and negative result on bone scan. The use of new imaging modalities, such as magnetic resonance imaging of thebone marrow and positron emission tomographic, scanning, may optimize staging evaluation. Multiple prognostic parameters have been identified for patients with SCLC, the most important of which are the stage or extent of disease, performance status, serum lactate dehydrogenase level, and male gender. identification of risk factors for treatment-related mortality is Important for the management of patients with SCLC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 16:12:14